Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patients with pre-existing cardiovascular risk factors, diabetes, or sleep apnea face elevated susceptibility to this condition
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected
Clinical studies have reported possible effects such as digestive symptoms, altered skin sensations and temporary heart rate changes, while researchers continue assessing its long-term safety profile
Gynecol Endocrinol 2015;31(2):131-5
You should speak with a healthcare provider if you: Have high blood pressure and are considering tirzepatide Currently take blood pressure medication Experience dizziness or symptoms of low blood pressure Notice significant changes in blood pressure readings Have concerns about your heart health Regular monitoring can help ensure safe and effective treatment
Doctors may also prescribe Ozempic off-label for weight loss
US$ 29.64
US$ 26.92
US$ 27.84
